Posted by Michael Wonder on 03 Feb 2023
Improved access to PBS medicines for pulmonary arterial hypertension
3 February 2023 - Access to pulmonary arterial hypertension PBS medicines has further improved as an outcome of the post-market review of pulmonary arterial hypertension medicines.
Effective 1 December 2022, pulmonary arterial hypertension patients with World Health Organisation functional class III or IV symptoms have access to endothelin receptor antagonist and prostanoid medicines for dual therapy.
